Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Receivables (2017 - 2024)

Protagonist Therapeutics' Change in Receivables history spans 8 years, with the latest figure at $165.0 million for Q4 2024.

  • For Q4 2024, Change in Receivables rose 1550.0% year-over-year to $165.0 million; the TTM value through Dec 2024 reached $155.0 million, up 1451.55%, while the annual FY2024 figure was $155.0 million, 1451.55% up from the prior year.
  • Change in Receivables for Q4 2024 was $165.0 million at Protagonist Therapeutics, up from -$43000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $290.0 million in Q1 2024 and bottomed at -$300.0 million in Q2 2024.
  • The 5-year median for Change in Receivables is -$41000.0 (2023), against an average of $7.9 million.
  • The largest YoY upside for Change in Receivables was 707321.95% in 2024 against a maximum downside of 2499900.0% in 2024.
  • A 5-year view of Change in Receivables shows it stood at -$363000.0 in 2020, then tumbled by 195.32% to -$1.1 million in 2021, then surged by 89.27% to -$115000.0 in 2022, then surged by 8795.65% to $10.0 million in 2023, then skyrocketed by 1550.0% to $165.0 million in 2024.
  • Per Business Quant, the three most recent readings for PTGX's Change in Receivables are $165.0 million (Q4 2024), -$43000.0 (Q3 2024), and -$300.0 million (Q2 2024).